Reports Third Quarter Revenues of $11.0 Billion
Posts Third Quarter GAAP Earnings Per Share of $0.93 and Non-GAAP EPS of $2.00; Includes Net Impact of Per Share for GAAP and Non-GAAP EPS Due to.
Bristol Myers Squibb (BMY) could become a leader in cell therapy - a market that could be worth $50b within five years. Read about my thoughts on Century deal.